IIRC we chose not to go with RespireRX. We instead have sourced...

IIRC we chose not to go with RespireRX. We instead have sourced dronabinol from MYODERM North America.
So now I can comfortably say....
Trial #1 Perionditis = Source: AXIM Products
Trial #2 Sleep Apnea = Source: MYODERM North America
Trials #3 and #4 - TMJ and Concussion = Source: Linnea SA
Generic Oils = Source: Linnea SA
According to Dr Sud 1000 patients by EOY, for reference 200M MC+ Althea Group only with ~1450 with increase from ~350 in 6 months by partnering with Dr Sud's CannVaLate, which we are too and have equity in us.

I think that's everything in terms of supply agreements done. Now its time to actually do the work!
Gonna have our ups and downs in the short term but no doubt the actual tangible important newsflow to come in the latter half of the year is supercharged. Very important to differentiate between substantial news vs news the market doesnt care about. IHL likes to spit out a lot of news but I have noticed that the market will only respond kindly to something MedCann related that has not already been priced in or told about.

Time for supply is over, now we look forward to seeing the boys get the job done. Good stuff!